3M licensed its dry powder drug delivery device for asthma and chronic obstructive pulmonary disease to Adamis for an undisclosed amount, granting the smaller company worldwide rights to bolster its own line of delivery devices.
After partners Regeneron and Sanofi announced more than 10 late-stage studies last year, Regeneron revealed plans Tuesday to take a shot at a trial to test less frequent dosing of the experimental therapy.
CRO inVentiv Health is teaming up with Oncobiologics to develop biosimilars of some of world's top-selling treatments, signing up to helm clinical trials and help get the knockoffs on the market.
The Cranbury, NJ-based biotech says they will focus on knockoffs of Humira, Rituxan, Avastin, Herceptin and Erbitux.
Just a few weeks after closing a research pact on rare diseases with Alexion, Cambridge, MA-based Ensemble Therapeutics has come away from the deal table with a major league partner for their in-house IL-17 agonist program. Novartis is in-licensing the anti-inflammatory work, Ensemble's most advanced preclinical program, adding another marquee name to the biotech's roster of collaborators.
Shares of Israel's Compugen soared more than 60% this morning after the Israeli biotech signed on to a collaboration with Bayer to find new antibody-based cancer immunotherapies.
Clinipace has struck a deal with Finland's Medfiles, allowing the North Carolina CRO to offer its clients services across the Nordics and Baltic countries.
Theraclone Sciences has struck a deal to merge its antibody development efforts with biodefense drug developer PharmAthene. Once the merger is complete, Theraclone CEO Clifford Stocks will head the expanded company as PharmAthene CEO Eric Richman takes a spot on the board.
La Jolla Institute for Allergy and Immunology and Kyowa Hakko Kirin California, a subsidiary of Japanese pharmaceutical company Kyowa Hakko Kirin, have signed a 6-year drug discovery pact to develop therapies for a wide range of autoimmune diseases.
AstraZeneca CEO Pascal Soriot has taken another step forward in his turnaround campaign, committing $350 million in cash and up to $465 million in milestones to partner up with FibroGen as it positions a lead anemia drug for late-stage trials.